慢性阻塞性肺病 (COPD) - 至2023年的流行病學的預測

由於 慢性阻塞性肺病 (COPD) ，是引起呼吸困難和呼吸急促、喘鳴、胸部壓迫感等症狀的疾病，根據WHO認為到2030年成為第3大死因。在全球8大市場中，慢性阻塞性肺病的患病數量預計從2013年的約6,423萬件以年率1.49％擴大，2023年增加到7,380萬。

本報告提供慢性阻塞性肺病的概要與風險因素、全球8大市場的趨勢，以及今後的流行病學的預測彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

• 疾病的背景
• 風險因素和共生病症
• 全球的趨勢
  • 美國
  • 歐洲5個國家
  • 日本及澳洲
• 預測方法
  • 使用的資訊來源
  • 未使用的資訊來源
  • 預測方法與假設
• 流行病學的預測
  • 患病數量
  • 各年齡患病數量
  • 性別患病數量
  • 年齡標準化數量
  • 各重度數量
  • 確診數量
  • 各年齡確診數量
  • 性別確診數量
  • 年齡評估確診數量
  • 各重度確診數量
  • 有共生病症的確診數量
  • 存活1年的確診數量
• 考察
  • 流行病學的預測
  • 分析的限制
  • 分析的優勢

第4章 附錄

圖表

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD (NHLBI, 2013).

In the 8MM, epidemiologists forecast that the total prevalent cases of COPD will increase from 65,991,432 cases in 2015 to 76,066,482 cases in 2025 at an Annual Growth Rate (AGR) of 1.53%. The US will have the highest number of total prevalent cases of COPD among the 8MM throughout the forecast period with 33,028,213 cases in 2015 and 39,284,075 cases in 2025.The US had the highest number of diagnosed prevalent cases of COPD in the 8MM in both 2015 and 2025, at 13,791,975 cases in 2015, and 16,033,432 cases in 2025.

The report "EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35-44, 45-54, 55-64, 65-74, and 75 years and older).

Scope

• The Chronic obstructive pulmonary disease (COPD) EpiCast Report provides an overview of the risk factors and global trends of COPD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the total prevalent cases of COPD (diagnosed and undiagnosed cases) and the diagnosed prevalent cases of COPD, which are segmented by sex and age (35-44, 45-54, 55-64, 65-74, and 75 years and older). The diagnosed prevalent cases of COPD are further segmented by the new GOLD 2011 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
• The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The COPD EpiCast report will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global COPD market.
• Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
• Understand severity stages of COPD cases by CAT score and mMRC scores.

Table of Contents

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 3
• 1.2 List of Figures 3

2 Chronic Obstructive Pulmonary Disease: Executive Summary 4

• 2.1 Related Reports 6

3 Epidemiology 7

• 3.1 Disease Background 7
• 3.2 Risk Factors and Comorbidities 8
• 3.3 Global and Historical Trends 9
• 3.4 Forecast Methodology 11
• 3.4.1 Sources 13
• 3.4.2 Forecast Assumptions and Methods 15
• 3.4.3 Total Prevalent Cases 16
• 3.4.4 Diagnosed Prevalent Cases 18
• 3.4.5 Diagnosed Prevalent Cases of COPD by Severity 21
• 3.5 Epidemiological Forecast for COPD (2015-2025) 22
• 3.5.1 Total Prevalent Cases of COPD 22
• 3.5.2 Age-Specific Total Prevalent Cases of COPD 23
• 3.5.3 Sex-Specific Total Prevalent Cases of COPD 25
• 3.5.4 Diagnosed Prevalent Cases of COPD 26
• 3.5.5 Age-Specific Diagnosed Prevalent Cases of COPD 27
• 3.5.6 Sex-Specific Diagnosed Prevalent Cases of COPD 28
• 3.5.7 Diagnosed Prevalent Cases of COPD by Severity 29
• 3.6 Discussion 30
• 3.6.1 Epidemiological Forecast Insight 30
• 3.6.2 Limitations of Analysis 31
• 3.6.3 Strengths of Analysis 31

4 Appendix 32

• 4.1 Bibliography 32
• 4.2 About the Authors 35
• 4.2.1 Epidemiologist 35
• 4.2.2 Reviewers 35
• 4.2.3 Global Director of Therapy Analysis and Epidemiology 36
• 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
• 4.3 About GlobalData 36
• 4.4 Contact Us 37
• 4.5 Disclaimer 37

List of Tables

1.1 List of Tables

• Table 1: Risk Factors and Comorbidities for COPD 9
• Table 2: New GOLD 2011 Criteria for COPD Severity Stages 12
• Table 3: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years 2015-2025 23
• Table 4: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015. 24
• Table 5: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years 2015-2025 26
• Table 6: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 27

List of Figures

1.2 List of Figures

• Figure 1: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, 2015 and 2025 5
• Figure 2: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, 2015 and 2025 6
• Figure 3: 8MM, Age-Standardized Total Prevalence of COPD (%), Ages ≥35 Years, 2015 10
• Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Ages ≥35 Years, 2015 11
• Figure 5: 8MM, Sources Used and Not Used to Forecast Total Prevalent Cases of COPD 13
• Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of COPD 14
• Figure 7: 8MM, Sources Used to Forecast the new GOLD 2011 Severity Stages Among the Diagnosed Prevalent Cases of COPD 15

Figure 8 : 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015 24

• Figure 9: 8MM, Sex-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2015 25
• Figure 10: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 27
• Figure 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N, 2015 28
• Figure 12: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using mMRC), Both Sexes, 2015 29
• Figure 13: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage (Using CAT), Both Sexes, 2015 30